Abstract 4363463: The Association of AHA Cardiovascular-Kidney-Metabolic Syndrome and PREVENT ASCVD Risk with Abdominal Aortic Calcification in US Adults
Abstract
Background: Abdominal aortic calcification (AAC) is a marker of subclinical atherosclerotic cardiovascular disease (ASCVD). Cardiovascular-kidney-metabolic (CKM) syndrome reflects dysfunction across cardiovascular, renal, and metabolic systems. The relationship between AAC and CKM is poorly understood. This study examined associations of CKM stages and predicted 10-year ASCVD risk with AAC in US adults aged ≥40 years. Methods: This cross-sectional study used National Health and Nutrition Examination Survey (NHANES) 2013–2014 data. AAC was measured by dual-energy X-ray absorptiometry and scored via the Kauppila method (range: 0–24). AAC was categorized as absent (score = 0), present (score > 0 to ≤ 6), and severe (score > 6). CKM stages (0–3+) were characterized as follows: Stage 0 included healthy individuals with normal BMI and waist circumference without other risk factors; Stage 1 included elevated BMI/waist circumference or prediabetes; Stage 2 included hypertension, diabetes, hypertriglyceridemia, metabolic syndrome, or moderate-to-high-risk CKD; Stage 3+ included very-high-risk CKD or ASCVD risk ≥20%. Multivariable linear and multinomial logistic regression were used to examine associations of ASCVD risk and CKM stage with AAC. Results: A total of 3140 participants (mean age 57.4 years, 48.1% male, 71% Non-Hispanic White) were included. Mean AAC scores progressively increased across CKM stages: 0.42 (stage 0), 0.81 (stage 1), 1.96 (stage 2), and 4.61 (stage 3+) (p<0.001). Each 10% ASCVD risk increase correlated with a 1.46-point higher AAC score (95% CI: 1.19–1.74). CKM stage 3+ was linked to a 1.16-point higher AAC score vs. stage 0 (95% CI: 0.43–1.89). Odds of any AAC increased 80% per 10% ASCVD increase (OR=1.80; 95% CI: 1.47–2.20), and odds of severe vs. absent AAC were over threefold higher (OR=3.45; 95% CI: 2.78–4.28). CKM stage 3+ had 3.38-fold greater odds of severe vs. absent AAC (95% CI: 1.29–8.86). Race/ethnicity modified AAC–ASCVD (p<0.01) and AAC–CKM (p<0.01) associations. Compared to stage 0, CKM stage 3+ was linked to AAC score increases of 3.37 (95% CI: 2.61–4.12) in Non-Hispanic White, 3.66 (95% CI: 1.75–5.57) in Asian, 2.01 (95% CI: 0.974-3.060) in Non-Hispanic Black, and 1.76 (95% CI: 0.40–3.13) in Hispanic populations. Conclusions: CKM stage and ASCVD risk are associated with AAC, with the magnitude of associations varying by race/ethnicity. AAC may serve as a useful imaging marker for early cardiometabolic risk detection.
Article Details
Authors (6)
Prem Patel
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Neal Pohlman
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Amaris Williams
The Ohio State University, Columbus, Ohio, United States
Songzhu Zhao
The Ohio State College of Medicine, Columbus, Ohio, United States
Guy Brock
Joshua Joseph
The Ohio State University, Columbus, Ohio, United States